Drug Profile
TH 9411
Latest Information Update: 14 Feb 2008
Price :
$50
*
At a glance
- Originator Theratechnologies
- Class Antivirals; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 18 Apr 2003 Vpr protein has been licensed to Merck & Co. in the US
- 20 Feb 1997 Preclinical development for HIV infections treatment in Canada (unspecified route)